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The incidence of gastric carcinoma is high among Japanese. The
recent development of early diagnostic methods has improved the
prognoses of patients with gastric carcinoma. However, prognoses
remain unsatisfactory in patients with advanced gastric carcinoma. 
There are many histological classifications of gastric carci-
noma. Gastric carcinomas were classified into the intestinal type
and the diffuse type by Lauren (1965), and into papillary adeno-
carcinoma (PAP), tubular adenocarcinoma (TUB), poorly dif-
ferentiated adenocarcinoma (POR), signet-ring cell carcinoma
(SIG) and mucinous adenocarcinoma (MUC) in the Japanese
Classification of Gastric Carcinoma (1995). To evaluate the
biological role of sialyl Lewisx antigen (SLX) depending on histo-
logic subtype in the present study, we classified gastric carcinomas
into differentiated type and undifferentiated type as follows:
differentiated carcinoma consisted of PAP, TUB and MUC which
arose from PAP or TUB, and undifferentiated carcinoma of POR,
SIG and MUC which arose from POR or SIG. Differentiated carci-
noma corresponds to the intestinal type according to Lauren, and
undifferentiated carcinoma to the diffuse type. The proportions of
both men and older patients are greater among the differentiated
carcinoma patients than the undifferentiated carcinoma patients
(Lauren, 1965; Wronkowsky et al, 1977). With respect to the
metastatic pattern, differentiated carcinoma tends to metastasize to
the liver, and undifferentiated carcinoma to the peritoneum
(Ignacio and Osvaldo, 1981; Rhomberg and Gruber, 1989; Esaki et
al, 1990; Mori et al, 1995). 
Carbohydrate antigens including SLX and sialyl Lewisa antigen
have been used as tumour markers of many carcinomas, including
gastric carcinoma. It was reported that these carbohydrate antigens
are ligands for selectin, an adhesion molecule expressed on the
vascular endothelial cells (Lowe et al, 1990; Phillips et al, 1990;
Walz et al, 1990; Takada et al, 1991). In vitro study showed that
these carbohydrates were involved in the adhesion of tumour cells
from gastric carcinoma, colon carcinoma, hepatoma, pancreatic
carcinoma and lung carcinoma to E-selectin, which is present on
cytokine-activated human endothelial cells (Takada et al, 1993). It
was also reported that colon carcinoma cells which were highly
metastatic to the liver expressed relatively more SLX structures
than their corresponding low metastatic counterparts, and that the
increased expression of SLX correlated with strong adherence to
vascular endothelial cells with E-selectin (Saitoh et al, 1992;
Sawada et al, 1992; Izumi et al, 1995; Bresalier et al, 1996). These
findings suggest that SLX play important roles during haemato-
geneous tumour metastasis. However, regarding the mechanism of
peritoneal dissemination, Nakashio et al (1997) suggested that
SLX was not involved in peritoneal dissemination. 
In recent years, correlations between the expression of these
carbohydrates and outcomes have been reported for various
tumours, although some studies have yielded conflicting results
(Nakagoe et al, 1993; Nakamori et al, 1993, 1997; Narita et al,
1993; Ogawa et al, 1994; Jorgensen et al, 1995; Nakayama et al,
1995; Amado et al, 1998). Information regarding the significance
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1997; Ura et al, 1997; Amado et al, 1998). These studies did not
satisfactorily mention the differences based on the histologic
types. 
In the present study, we evaluated the clinicopathologic
significance of SLX in patients with advanced gastric carcinoma,
who had undergone gastric resections between January, 1980 
and December, 1981. We classified gastric carcinomas into
differentiated type, in which liver metastasis was more common,
and undifferentiated type, which had more frequent peritoneal
dissemination. Based on the hypothesis that the influence of 
SLX expression may have been obscured by distinct biological
roles depending on histologic subtypes, we also analysed 
the clinicopathologic significance of SLX expression in 
subsets of patients with differentiated and undifferentiated
carcinoma. 
MATERIALS AND METHODS 
Patients 
We studied 245 patients with advanced gastric carcinoma who
underwent consecutive gastrectomies at Aichi Cancer Center
Hospital between January, 1980 and December, 1981. They were
followed well for 10 years. Histologically, they were divided into
91 patients with differentiated carcinoma and 154 with undifferen-
tiated carcinoma. Tumour stage and curative potential of the
gastric resection were classified by the Japanese Classification of
Gastric Carcinoma (1995). In this study, tumour stages III and IV
were regarded as advanced tumour stages. Lymphadenectomy was
performed on 242 patients. 
The proportions of men and older patients were greater 
among cases of differentiated than undifferentiated carcinomas 
(P < 0.0001 and P < 0.0001, respectively). Moreover, the inci-
dence of invasion to the serous membrane was significantly lower
with differentiated carcinoma than with undifferentiated carci-
noma (P = 0.0002). The incidence of synchronous liver metastases
at surgery was significantly higher (P = 0.021) among differenti-
ated than among undifferentiated carcinoma patients, while the
incidence of synchronous peritoneal dissemination at surgery was
significantly lower (P = 0.023) among differentiated than among
undifferentiated carcinoma patients (Table 1). Gastric resections
for 198 patients were regarded as potentially curative (Resection A
and Resection B according to the Japanese Classification of
Gastric Cancer (1995)), and for 47 patients as noncurative
(Resection C according to the Japanese Classification of Gastric
Cancer (1995)). Of 198 patients who underwent potentially 
curative resection, 91 patients died of a recurrence of the gastric
carcinoma and 20 of some other disease. 
Antibody 
Immunostaining was performed using SNH-3, a monoclonal anti-
body against SLX (IgM, kindly supplied by Dr Sen-itiroh Hakomori,
Pacific Northwest Research Foundation, Seattle, WA, USA). 
Immunohistochemical staining and evaluation 
The tissue specimens were fixed in 10% neutral-buffered
formaldehyde solution, embedded in paraffin, and cut into 5 µ m
sections. An avidin-biotin complex technique was used. Each
reaction was carried out at room temperature. In brief, endogenous
peroxidase activity was blocked by 0.3% hydrogen peroxide in
methanol. Tissue specimens were reacted with SNH-3 antibody
for 1 hour in a moist chamber. Subsequently, tissue specimens
were reacted with anti-mouse IgG, avidin-biotin complex
(Vectastatin ABC kit, Vecter, Burlingame, CA), and 3,3′ -
diaminobenzidine tetrahydrochloride. The specimens were coun-
terstained with haematoxylin. The stained tissue specimens were
evaluated by 2 of the authors. Based on the ratio of SLX-
positive cells, the positivity of the tumour cells was classified as
follows: 
(–): less than 10% of tumour cells were positive for SLX; 
(+): 10% or more of tumour cells were positive for SLX. 
Staining of elastic fibres 
To evaluate the presence of venous invasion, Victoria blue stain
(Tsutsumi et al, 1990) was used to stain elastic fibres. 
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Table 1 Cinicopathological features of 245 patients with advanced gastric carcinoma 
Total n = 245 (%) Differentiated carcinoma n = 91 (%) Undifferentiated carcinoma n = 154 (%) P value 
Average age 56.9 ± 12.0 63.4 ± 9.5 53.1 ± 12.0 P <0.0001 
Sex 
Male 163 (67) 76 (84) 87 (56) P <0.0001 
Female 82 (33) 15 (16) 67 (44) 
Serosal invasion 
Positive 136 (56) 36 (40) 100 (65) P = 0.0002 
Lymph node metastasis 
Positive 173/242 (71) 1/90 (68) 112/152 (74) P = 0.40 
Venous invasion 
Positive 118 (48) 49 (54) 69 (45) P = 0.22 
Liver metastasis 
Positive 7 (3) 6 (7) 1 (0.6) P = 0.021 
Peritoneum dissemination 
Positive 30 (12) 5 (5) 25 (16) P = 0.023 
Stage 
I (I a + I b) 48 (20) 22 (24) 26 (17) P = 0.11 
II 45 (18) 21 (23) 24 (16) 
III (IIIa + IIIb) 97 (40) 33 (36) 64 (42) 
IV (IVa + IVb) 55 (22) 15 (16) 40 (26)Statistical analysis 
Respective factors were compared by the χ 2 test or Student’s t-test.
Survival rates were calculated by the Kaplan-Meier method, and
statistical significance was tested with a generalized Wilcoxon
test. 
RESULTS 
Relationship between recurrent site and histologic
types 
Of the 79 patients with differentiated carcinoma who underwent
potentially curative resection, 34 patients died of gastric carcinoma
recurrence and 11 of other diseases. The initial diagnoses of recur-
rent tumors were as follows: liver metastasis in 13 (38%) patients,
peritoneal dissemination in 11 (32%) patients, and recurrent tumour
from other sites in 10 (29%) patients. Of the 119 patients with
undifferentiated carcinoma who underwent potentially curative
resection, 57 patients died of a recurrence of gastric carcinoma and
9 of other diseases. The initial diagnoses of recurrent tumours were
as follows: peritoneal dissemination in 37 (65%) patients, liver
metastasis in one (1%) patient, and recurrent tumour from other
sites in 19 (33%) patients. Statistical analysis revealed that the
incidence of recurrence in the liver was significantly higher 
(P < 0.0001) among patients with differentiated carcinoma than
among those with undifferentiated carcinoma, while the incidence
of recurrence in the peritoneum was significantly higher 
(P < 0.0096) among patients with undifferentiated carcinoma than
among those with differentiated carcinoma (Table 2). 
Expression of SLX 
In cancerous gastric tissue, positive staining for SLX was mainly
observed in cell membranes and cytoplasm (Figure 1). Positive
SLX staining was sometimes obtained in the extracellular mucus. 
Relationship between SLX expression and
clinicopathologic features in patients with advanced
gastric carcinoma 
The correlations of SLX expression with different clinicopatho-
logic features are shown in Table 3. Among 245 patients with
advanced gastric carcinoma, SLX was positive in 135 (55%)
patients, including 68 (75%) with differentiated carcinoma and 67
(44%) with undifferentiated carcinoma. The rate of positive SLX
expression was significantly higher among differentiated carci-
noma patients than among undifferentiated carcinoma patients 
(P < 0.0001). The incidence of differentiated carcinoma, venous
invasion and lymph node metastasis was significantly higher 
(P < 0.0001,  P = 0.016 and P = 0.0037, respectively) in SLX-
positive patients than in SLX-negative ones. No significant
correlations were found between SLX expression and the other
clinicopathologic features.
Relationship between SLX expression and
clinicopathologic features in patients with
differentiated carcinoma 
The correlations of SLX expression with different clinicopatho-
logic features are shown in Table 4. SLX was positive in 68 (75%)
of 91 patients with differentiated carcinoma. The incidence of
lymph node metastasis and advanced tumour stage were signifi-
cantly higher (P < 0.0001 and P = 0.0065, respectively) in SLX-
positive patients than in SLX-negative ones. No significant
correlations were found between SLX expression and the other
clinicopathologic features. The 6 patients with synchronous liver
metastasis at surgery were all positive for SLX. 
Relationship between SLX expression and
clinicopathologic features in patients with
undifferentiated carcinoma 
The correlations of SLX expression with different clinicopatho-
logic features are shown in Table 5. SLX was positive in 67 (44%)
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Table 2 Postoperative liver metastasis and peritoneal dissemination in patients with curative resoction 
Total n = 198 (%) Differentiated carcinoma n = 79 (%) Undifferentiated carcinoma n = 119 (%) P value 
Liver metastasis 14 (7) 13 (16) 1 (1) P <0.0001 
Peritoneal dissemination 48 (24) 11 (14) 37 (31) P = 0.0096 
Figure 1 In cancerous gastric tissue, SLX expression was located mainly
on the cell membrane and in the cytoplasm. (A) differentiated carcinoma,
(B) undifferentiated carcinoma (original magnification × 100) of 154 patients with undifferentiated carcinoma. There was no
significant difference between SLX expression and any clinico-
pathologic features. 
Relationship between SLX expression and 
survival 
In survival analysis with advanced gastric carcinoma (n = 245),
there was no significant difference between SLX expression and
survival (Figure 2). 44 (49%) of 110 SLX-negative patients and 84
(62%) of 135 SLX-positive ones died of gastric carcinoma,
indicating no significant difference in mortality from gastric
carcinoma between SLX-negative and SLX-positive patients. 
With differentiated carcinoma (n = 91), the prognoses of 
SLX-positive patients were significantly poorer than those of 
SLX-negative patients (P = 0.019, Figure 3). 4 (17%) of 23 SLX-
negative patients and 42 (62%) of 68 SLX-positive ones died
of gastric carcinoma, indicating that mortality from gastric
carcinoma was significantly higher in the latter than in the former
(P = 0.0006). 
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Table 3 Relationship between SLX staining status and clinicopathologic features in patients with advanced gastric carcinoma 
SLX (–) n = 110 (%) SLX (+) n = 135 (%) P value 
Age 
≥ 57 52 (47) 72 (53) P = 0.41 
57> 58 (53) 63 (47) 
Sex 
Male 69 (63) 94 (70) P = 0.24 
Female 41 (37) 41 (30) 
Histologic type 
Differentiated type 23 (21) 68 (50) P <0.0001 
Undifferentiated type 87 (79) 67 (50) 
Serosal invasion 
Positive 64 (58) 71 (53) P = 0.46 
Venous invasion 
Positive 44 (40) 76 (56) P = 0.016 
Lymph node metastasis 
Positive 68 (62) 105/132 (80) P = 0.0037 
Liver metastasis 
Positive 1 (0.9) 6 (4) P = 0.21 
Peritoneum dissemination 
Positive 15 (14) 15 (11) P = 0.69 
Stage 
I + II 48 (44) 45 (33) P = 0.13 
III + IV 62 (56) 90 (67) 
Curability of resection 
Potentially curative 88 (80) 110 (71) P = 0.90 
Noncurative 22 (20) 2 5(19) 
Table 4 Relationship between SLX staining status and clinicopathologic features in patients with differentiated carcinoma 
SLX (–) n = 23 (%) SLX (+) n = 68 (%) P value 
Age 
≥ 65 16 (70) 31 (46) P = 0.08 
65> 7 (30) 37 (54) 
Sex 
Male 21 (91) 55 (81) P = 0.40 
Female 2 (9) 13 (19) 
Serosal invasion 
Positive 6 (26) 30 (44) P = 0.24 
Venous invasion 
Positive 10 (43) 39 (57) P = 0.36 
Lymph node metastasis 
Positive 7 (30) 54/67 (81) P <0.0001 
Liver metastasis 
Positive 0 6 (9) P = 0.32 
Peritoneal dissemination 
Positive 0 5 (7) P = 0.42 
Stage 
I + II 17 (74) 26 (38) P = 0.0065 
III + IV 6 (26) 42 (62) 
Curability of resection 
Potentially curative 23 (100) 56 (82) P = 0.07 
Noncurative 0 12 (18)With undifferentiated carcinoma (n = 154), there was no signifi-
cant difference between SLX expression and survival (Figure 4).
50 (57%) of 87 SLX-negative patients and 42 (63%) of 67 SLX-
positive ones died of gastric carcinoma, indicating no significant
difference in mortality from gastric carcinoma between SLX-
negative and SLX-positive patients. 
Evaluation of SLX expression in patients who
underwent potentially curative resection and 
developed recurrent tumour in the liver or in the
peritoneum 
Among 198 patients with advanced gastric carcinoma who under-
went potentially curative resection, the incidence of recurrence
in the liver was significantly higher in SLX-positive patients 
than in SLX-negative ones (P = 0.0084). However, there was no
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Figure 2 Survival curves of patients with advanced gastric carcinoma,
subdivided according to SLX antigen expression 
Table 5 Relationship between SLX staining status and clinicopathologic features in patients with undifferentiated carcinoma 
SLX (–) n = 87 (%) SLX (+) n = 67 (%) P value 
Age 
≥ 54 40 (46) 39 (58) P = 0.18 
54> 47 (54) 28 (42) 
Sex 
Male 48 (55) 39 (58) P = 0.83 
Female 39 (45) 28 (42) 
Serosal invasion 
Positive 58 (67) 42 (63) P = 0.73 
Venous invasion 
Positive 34 (39) 37 (55) P = 0.067 
Lymph node metastasis 
Positive 61 (70) 51/65 (78) P = 0.33 
Liver metastasis 
Positive 1 (1) 0 P = 0.90 
Peritoneal dissemination 
Positive 15 (7) 10 (15) P = 0.87 
Stage 
I + II 31 (36) 19 (28) P = 0.43 
III + IV 56 (64) 48 (72) 
Curability of resection 
Potentially curative 65 (75) 54 (81) P = 0.50 
Noncurative 22 (25) 13 (19) 
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Figure 3 Survival curves of patients with differentiated carcinoma,
subdivided according to SLX antigen expression 
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Figure 4 Survival curves of patients with undifferentiated carcinoma,
subdivided according to SLX antigen expressionsignificant difference in the incidence of recurrence in the peri-
toneum between SLX-positive and SLX-negative patients. 
Among the 79 patients with differentiated carcinoma who under-
went potentially curative resection, no recurrence in the liver was
observed in 23 SLX-negative patients, while recurrence in the liver
was observed in 13 (23%) of 56 SLX-positive patients, demon-
strating a significantly higher incidence of liver recurrence in SLX-
positive patients than in SLX-negative ones (P = 0.028). There was
no significant difference in the incidence of recurrence in the peri-
toneum between SLX-negative and SLX-positive patients. 
Among the 119 patients with undifferentiated carcinoma who
underwent potentially curative resection, there were no significant
differences in the incidence of recurrence in the liver or in the
peritoneum between SLX-negative and SLX-positive patients 
(Table 6). 
DISCUSSION 
The present study demonstrated that differentiated carcinoma
tended to metastasize to the liver and undifferentiated carcinoma
to the peritoneum, which was consistent with previous studies
(Ignasio and Osvaldo, 1981; Rhomberg and Gruber, 1989; Esaki et
al, 1990; Mori et al, 1995). 
Previous studies regarding the significance of SLX expression
in gastric carcinoma are limited and have yielded conflicting
results (Nakamori et al, 1997; Ura et al, 1997; Amado et al, 1998).
Nakamori et al (1997) reported that SLX expression in gastric
carcinoma was not correlated with any clinicopathologic features.
However, Ura et al (1997) reported that SLX expression correlated
with increased risk of metastases and poor prognosis in gastric
carcinoma, and Amado et al (1998) reported that SLX expression
in gastric carcinoma was correlated with venous invasion and poor
outcome. These studies did not adequately mention the differences
based on the histologic types. The purpose in this study was to
determine whether the differentiated and undifferentiated types of
gastric carcinoma have different patterns in clinicopathologic
significance of SLX expression. 
Regarding the relationship between SLX positivity and histo-
logic type, only a few studies have been found in English litera-
tures, and yielded conflicting results (Dohi et al, 1989; Ikeda et al,
1996; Nakamori et al, 1997; Ura et al, 1997; Amado et al, 1998).
In the present study, the frequency of SLX positivity was signifi-
cantly higher among patients with differentiated carcinoma than
among those with undifferentiated carcinoma (P < 0.0001). 
There were distinct differences in the clinicopathologic signifi-
cance of SLX expression between cases of differentiated and
undifferentiated carcinoma. With differentiated carcinoma, there
were significant correlations between SLX expression and lymph
node metastasis, tumour stage, prognosis and tumour recurrence in
the liver. However, with undifferentiated carcinoma, there were no
significant correlations between the SLX expression and clinico-
pathologic features. 
The incidence of lymph node metastasis with differentiated
carcinoma were 30% and 81% in SLX-negative and SLX-positive
patients, respectively, indicating a significant difference between
the two (P< 0.0001). Although the biological significance of SLX
in lymph node metastasis remains unknown, this observation
suggests that SLX may play an important role in this type of
metastasis especially in cases of differentiated carcinoma. 
Notably, with differentiated carcinoma, SLX was positive in all
19 patients with synchronous liver metastasis and liver recurrence.
The incidence of liver recurrence was significantly higher in SLX-
positive patients than in SLX-negative ones (P= 0.028). These
results were consistent with the results of previous animal and in
vitro reports, which stated that SLX was a ligand carbohydrate of
selection and played an important role during haematogenous
metastasis (Saitoh et al, 1992; Sawada et al, 1992; Takada et al,
1993; Izumi et al, 1995; Bresalier et al, 1996). The present study
revealed that the frequencies of SLX positivity, synchronous liver
metastasis and liver recurrence were significantly higher with
differentiated carcinoma than with undifferentiated carcinoma
(P < 0.0001, P = 0.021 and P = 0.028, respectively). Therefore,
this high SLX expression appears to be closely related with the
higher frequency of liver metastasis in differentiated carcinoma. 
The survival rate of patients with SLX-positive tumours was sig-
nificantly lower (P= 0.019) than that of patients with SLX-negative
tumours in cases of differentiated carcinoma. The high incidence of
lymph node metastasis and liver metastasis may result in poor
outcome of SLX-positive patients with differentiated carcinoma. 
Peritoneal dissemination was a main metastatic pattern of undif-
ferentiated carcinomas. The present study showed no significant
correlations between SLX expression and peritoneal dissemination
in patients with advanced, differentiated or undifferentiated gastric
carcinomas. Several reports have recently been published which
deal with the mechanism of this dissemination. Using ovarian
carcinoma cells, Cannistra et al (1993) reported that CD44H was
involved in the adhesion of tumour cells to peritoneal mesothelial
cells. Some authors have subsequently described that CD44H
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Table 6 Relationship between SLX staining status and postoperative liver metastasis and peritoneal dissemination in patients with curative resection 
(a) Advanced gastric carcinoma SLX(–) n = 88 (%) SLX (+) n = 110 (%) P value 
Liver metastasis 1 (1) 13 (23) P = 0.0084 
Peritoneal dissemination 21 (24) 27 (25) P = 0.96 
(b) Differentiated carcinoma SLX (–) n = 23 (%) SLX(+) n = 56 (%) P value 
Liver metastasis 0 13 (23) P = 0.028 
Peritoneal dissemination 3 (13) 8 (14) P = 0.83 
(c) Undifferentiated carcinoma SLX (–) n = 65 (%) SLX(+) n = 54 (%) P value 
Liver metastasis 1 (2) 0 P = 0.93 
Peritoneal dissemination 18 (28) 19 (35) P = 0.50 plays an important role in peritoneal dissemination of a gastric
carcinoma (Nishimura et al, 1996; Nakashio et al, 1997). Using a
gastric carcinoma cell line which was established from undifferen-
tiated carcinoma (Akiyama et al, 1988) and had a high potential for
peritoneal dissemination, Nakashio et al (1997) indicated that both
CD44H and β 1 integrin were involved in peritoneal dissemination.
Interestingly, their flow-cytometric analysis indicated that SLX
expression was weak in the gastric carcinoma cells with a high
potential for peritoneal dissemination, and that peritoneal dissemi-
nation was not inhibited by anti-SLX antibody. SLX expression
may not influence the development of peritoneal dissemination. 
In conclusion, the clinicopathologic significance of SLX
expression in gastric carcinoma depended on histologic type. With
differentiated carcinoma, differences in SLX expression were
associated with lymph node metastasis, tumour stage, liver recur-
rence and prognosis. Expression of SLX may be of great relevance
in predicting the liver metastasis in patients with differentiated
carcinoma. But there were no significant correlations between the
SLX expression and any clinicopathologic features in patients with
undifferentiated carcinoma. 
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